Ultragenyx price target lowered to $43 from $44 at Barclays

Barclays analyst Eliana Merle lowered the firm’s price target on Ultragenyx (RARE) to $43 from $44 and keeps an Overweight rating on the shares. The firm says the company’s valuation is attractive on its base business cash flows. The Angelman data could drive shares up 50%-100% if positive versus downside of 30%-40% on a miss, the analyst tells investors in a research note.